Rare lephants
Screener

Co-Diagnostics, Inc.

CODX ·Healthcare, Medical Devices, United States
Analysis › Moat Score

Moat Score — Co-Diagnostics, Inc.

Total Moat Score 7 / 30
Moat Factor Score Analysis
Intangible Assets Patents, trademarks, brand strength, or regulatory licenses that protect a company's products or services from being freely copied by competitors. 3 / 5 Co-Primers chemistry is protected by 20+ granted/pending patents and provides a genuine, differentiated technical claim on reducing false positives.
Cost Advantage A durable ability to produce goods or services more cheaply than competitors — through scale, unique access to cheap inputs, location, or process — that lets a company undercut rivals or out-earn them at the same price. 2 / 5 Owning core primer IP outright avoids royalty payments and JV manufacturing in India lowers production cost, but overall scale is far below major diagnostics peers.
Pricing Power The ability to raise prices without losing meaningful business, because the product or service is differentiated, mission-critical, or has few good substitutes. 1 / 5 Competes largely on affordability against Roche, Abbott and QIAGEN, limiting ability to command premium pricing.
Network Effect The product or service becomes more valuable to every user as more people or organizations use it, making an established leader harder to displace. 0 / 5 No network effect; value is embedded in proprietary chemistry and manufacturing, not user/data networks.
Switching Costs The money, time, or operational disruption a customer would face switching to a competitor, which locks in existing customers and supports renewals. 1 / 5 Laboratory customers can switch PCR test suppliers relatively easily; some stickiness exists once a lab's workflow is validated around a specific platform.
Efficient Scale A market that can only profitably support a small number of players, so incumbents face limited threat from new entrants even without other defenses. 0 / 5 The molecular diagnostics market comfortably supports many large, well-capitalized players, so there is no efficient-scale barrier protecting Co-Diagnostics' niche position.